Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | glutathione reductase | 0.0037 | 0.0028 | 0.5 |
Mycobacterium tuberculosis | Probable NADH dehydrogenase Ndh | 0.0084 | 0.0769 | 0.0891 |
Mycobacterium tuberculosis | Putative ferredoxin reductase | 0.0084 | 0.0769 | 0.0891 |
Mycobacterium tuberculosis | Dihydrolipoamide dehydrogenase LpdC (lipoamide reductase (NADH)) (lipoyl dehydrogenase) (dihydrolipoyl dehydrogenase) (diaphoras | 0.0093 | 0.0916 | 0.1069 |
Plasmodium falciparum | thioredoxin reductase | 0.0037 | 0.0028 | 0.5 |
Mycobacterium tuberculosis | Probable membrane NADH dehydrogenase NdhA | 0.0084 | 0.0769 | 0.0891 |
Mycobacterium tuberculosis | Probable nitrite reductase [NAD(P)H] large subunit [FAD flavoprotein] NirB | 0.0084 | 0.0769 | 0.0891 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0037 | 0.0028 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | N-acetylglucosamine-1-phosphate uridyltransferase | 0.0564 | 0.8339 | 0.5 |
Brugia malayi | glutathione reductase | 0.0037 | 0.0028 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0 | 0.5 |
Echinococcus granulosus | thioredoxin glutathione reductase | 0.0037 | 0.0036 | 0.0036 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0 | 0.5 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0093 | 0.0916 | 0.0194 |
Plasmodium vivax | glutathione reductase, putative | 0.0037 | 0.0028 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0103 | 0.108 | 0.1265 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0037 | 0.0028 | 0.5 |
Schistosoma mansoni | microtubule-associated protein tau | 0.067 | 1 | 1 |
Mycobacterium tuberculosis | NAD(P)H quinone reductase LpdA | 0.0093 | 0.0916 | 0.1069 |
Treponema pallidum | licC protein (licC) | 0.0103 | 0.108 | 0.5 |
Plasmodium falciparum | glutathione reductase | 0.0037 | 0.0028 | 0.5 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.0037 | 0.0036 | 0.0036 |
Echinococcus multilocularis | microtubule associated protein 2 | 0.067 | 1 | 1 |
Brugia malayi | Thioredoxin reductase | 0.0037 | 0.0028 | 1 |
Mycobacterium tuberculosis | Probable dehydrogenase | 0.0084 | 0.0769 | 0.0891 |
Loa Loa (eye worm) | thioredoxin reductase | 0.0037 | 0.0028 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0 | 0.5 |
Leishmania major | trypanothione reductase | 0.0037 | 0.0028 | 0.5 |
Trypanosoma brucei | trypanothione reductase | 0.0037 | 0.0028 | 0.5 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0093 | 0.0916 | 0.1069 |
Mycobacterium tuberculosis | Probable reductase | 0.0084 | 0.0769 | 0.0891 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0103 | 0.108 | 0.1265 |
Mycobacterium ulcerans | bifunctional N-acetylglucosamine-1-phosphate uridyltransferase/glucosamine-1-phosphate acetyltransferase | 0.0564 | 0.8339 | 1 |
Mycobacterium tuberculosis | Probable UDP-N-acetylglucosamine pyrophosphorylase GlmU | 0.0564 | 0.8339 | 1 |
Toxoplasma gondii | eukaryotic initiation factor-2B, gamma subunit, putative | 0.0103 | 0.108 | 1 |
Mycobacterium leprae | Probable UDP-N-acetylglucosamine pyrophosphorylase GlmU | 0.0564 | 0.8339 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
MIC (functional) | = 0.002 ug ml-1 | In vitro antibacterial activity against aerobically grown Pasteurella multocida (59A006) | ChEMBL. | 1311762 |
MIC (functional) | = 0.01 ug ml-1 | In vitro antibacterial activity against aerobically grown Escherichia coli (51A538) | ChEMBL. | 1311762 |
MIC (functional) | = 0.01 ug ml-1 | In vitro antibacterial activity against Aerobically grown Pasteurella haemolytica (59B018) | ChEMBL. | 1311762 |
MIC (functional) | = 0.01 ug ml-1 | In vitro antibacterial activity against aerobically grown Salmonella choleraesuis (58B015) | ChEMBL. | 1311762 |
MIC (functional) | = 0.01 ug ml-1 | In vitro antibacterial activity against anaerobically grown Actinobacillus pleuropneumoniae (54B004) | ChEMBL. | 1311762 |
MIC (functional) | = 0.01 ug ml-1 | In vitro antibacterial activity against aerobically grown Escherichia coli (51A538) | ChEMBL. | 1311762 |
MIC (functional) | = 0.05 ug ml-1 | In vitro antibacterial activity against aerobically grown Staphylococcus aureus (54B004) | ChEMBL. | 1311762 |
MIC (functional) | = 0.1 ug ml-1 | In vitro antibacterial activity against anaerobically grown Bacteroides vulgatus (78D029) | ChEMBL. | 1311762 |
MIC (functional) | = 0.1 ug ml-1 | In vitro antibacterial activity against anaerobically grown Clostridium perfringens (10A009) | ChEMBL. | 1311762 |
MIC (functional) | = 0.39 ug ml-1 | In vitro antibacterial activity against aerobically grown Bordetella bronchiseptica (73A009) | ChEMBL. | 1311762 |
MIC (functional) | = 0.39 ug ml-1 | In vitro antibacterial activity against anaerobically grown Actinomyces pyogenes (14D002) | ChEMBL. | 1311762 |
MIC (functional) | = 0.39 ug ml-1 | E. coli DNA cleavage endpoint value which is the minimum amount required (in micro g/mL) to induce detectable cleavage of supercoiled pBR322 substrate to linear form (gyrase) | ChEMBL. | 1311762 |
MIC (functional) | = 0.39 ug ml-1 | E. coli DNA cleavage endpoint value which is the minimum amount required (in micro g/mL) to induce detectable cleavage of supercoiled pBR322 substrate to linear form (gyrase) | ChEMBL. | 1311762 |
MIC (functional) | = 0.78 ug ml-1 | In vitro evaluation for antibacterial activity against anaerobically grown Treponema hyodysenteriae (94A007) | ChEMBL. | 1311762 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.